Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (20%) |
| §103 only | 2 (40%) |
| No statute on record | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZOU, NIANXIANG | 1 | 64.3% | +24.2% |
| GURLEY, JAMI MICHELLE | 1 | 45.0% | +25.5% |
| DAHLIN, HEATHER RAQUEL | 1 | 46.5% | +48.9% |
| FISHER, MELISSA L | 1 | 44.2% | +42.3% |
| LEE, ANDREW P | 1 | 48.5% | +23.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | FISHER, MELISSA L | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, ANDREW P | 19d overdue |
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | FISHER, MELISSA L | 5d |
| 18279708 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DAHLIN, HEATHER RAQUEL | 15d |
| 18290356 | NOVEL PROTEIN AND NUCLEIC ACID SEQUENCES FOR COVID-19 VACCINES | ZOU, NIANXIANG | 40d |
| 18282357 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | GURLEY, JAMI MICHELLE | 43d |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1647 | 1 |
| 1629 | 1 |
| 1658 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18290356 | NOVEL PROTEIN AND NUCLEIC ACID SEQUENCES FOR COVID-19 VACCINES | ZOU, NIANXIANG | 1671 | §103 | Non-Final OA | 40d | Pending | Nov 13, 2023 |
| 18282357 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | GURLEY, JAMI MICHELLE | 1647 | Other | Non-Final OA | 43d | Pending | Sep 15, 2023 |
| 18279708 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DAHLIN, HEATHER RAQUEL | 1629 | Other | Non-Final OA | 15d | Pending | Aug 31, 2023 |
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | FISHER, MELISSA L | 1658 | §101 | Non-Final OA | 5d | Pending | Mar 03, 2023 |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, ANDREW P | 1691 | §103 | Final Rejection | 19d overdue | Pending | Aug 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial